CSL Ltd
ASX:CSL
CSL Ltd
Cost of Revenue
CSL Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
CSL Ltd
ASX:CSL
|
Cost of Revenue
-$6.9B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-11%
|
|
Immutep Ltd
ASX:IMM
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Opthea Ltd
ASX:OPT
|
Cost of Revenue
-$233.9k
|
CAGR 3-Years
18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
Mesoblast Ltd
ASX:MSB
|
Cost of Revenue
-$21.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cost of Revenue
AU$8.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cost of Revenue
-AU$188.2m
|
CAGR 3-Years
-353%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is CSL Ltd's Cost of Revenue?
Cost of Revenue
-6.9B
USD
Based on the financial report for Dec 31, 2023, CSL Ltd's Cost of Revenue amounts to -6.9B USD.
What is CSL Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-11%
Over the last year, the Cost of Revenue growth was -23%. The average annual Cost of Revenue growth rates for CSL Ltd have been -19% over the past three years , -14% over the past five years , and -11% over the past ten years .